ArticleBiology methods & protocols2026
Reverse vaccinology and immunoinformatics identify multi-epitope vaccine candidates against molluscum contagiosum virus.
Article in Biology methods & protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molluscum contagiosum virus (MCV) is a human-specific poxvirus responsible for a common contagious skin infection, yet no licensed prophylactic vaccine is available. Therefore, this study aimed to identify potential vaccine candidates against MCV using integrated reverse vaccinology and immunoinformatics approach. Candidate proteins involved in immune evasion, viral entry, and virion assembly were assessed for physicochemical properties, transmembrane topology, antigenicity, allergenicity, and toxicity. Linear B-cell, cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes were predicted and prioritized based on antigenicity, safety, HLA-binding affinity, and worldwide population coverage. The selected epitopes were assembled into a multi-epitope vaccine construct, followed by physicochemical characterization, secondary and tertiary structure prediction, and molecular docking analysis with Toll-like receptor 4 (TLR4). Eight candidate proteins were selected for immunoinformatics analysis, of which six were predicted to be antigenic. Five HTL epitopes, five CTL epitopes, and three non-toxic antigenic B-cell epitopes were selected, providing an estimated worldwide population coverage of 80.69%. The final 351-amino acid construct had a predicted molecular weight of 37.48 kDa, an instability index of 33.29, and a hydrophilic GRAVY value of -0.201. AlphaFold 3 produced a structurally organized model, while docking predicted a favorable interaction with TLR4 (score, -190.46) supported by hydrogen bonds, salt bridges, and electrostatic interactions. The vaccine construct exhibited favorable physicochemical properties, broad population coverage, structural stability, and strong interaction with TLR4, suggesting its potential as a prophylactic vaccine candidate. Nevertheless, further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.